{
    "root": "60081062-9f4b-4cf5-9c24-02b5a0b7f792",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Ezetimibe"
    },
    "value": "20250313",
    "ingredients": [
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE 2208 (3 MPA.S)",
            "code": "9H4L916OBU"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        }
    ],
    "indications": "ezetimibe tablets indicated : combination statin , alone additional low-density lipoprotein cholesterol ( ldl-c ) lowering therapy possible , adjunct diet reduce elevated ldl-c adults primary hyperlipidemia , including heterozygous familial hypercholesterolemia ( hefh ) . combination statin adjunct diet reduce elevated ldl-c pediatric patients 10 years age older hefh . combination fenofibrate adjunct diet reduce elevated ldl-c adults mixed hyperlipidemia . combination statin , ldl-c lowering therapies , reduce elevated ldl-c levels adults pediatric patients 10 years age older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet reduction elevated sitosterol campesterol levels adults pediatric patients 9 years age older homozygous familial sitosterolemia . ezetimibe tablets used combination statin , fenofibrate , ldl-c lowering therapies , refer prescribing information products information safe effective .",
    "contraindications": "recommended dose ezetimibe tablets 10 mg orally daily , administered without food . dose missed , take missed dose soon possible . double next dose . assess ldl-c clinically appropriate , early 4 weeks initiating ezetimibe tablets . administer ezetimibe tablets least 2 hours 4 hours bile acid sequestrant [ ( 7 ) ] .",
    "warningsAndPrecautions": "ezetimibe tablets usp , 10 mg white off-white , capsule shaped beveled edge tablets debossed `` k 31 `` one side plain side . supplied follows : bottles 30 ndc 59651-052-30 bottles 90 ndc 59651-052-90 bottles 500 ndc 59651-052-05 storage store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "ezetimibe tablets contraindicated patients known hypersensitivity ezetimibe excipients ezetimibe tablets . hypersensitivity including anaphylaxis , angioedema , rash , urticaria reported [ ( 6.2 ) ] . used combination statin , fenofibrate , ldl-c lowering therapy , ezetimibe tablets contraindicated patients statin , fenofibrate , ldl-c lowering therapy contraindicated . refer prescribing information products list [ ( 5.1 ) ] .",
    "indications_original": "Ezetimibe tablets are indicated:\n                  \n                     In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).\n                     In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.\n                     In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia.\n                     In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.\n                  \n                  When ezetimibe tablets are used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.",
    "contraindications_original": "The recommended dose of ezetimibe tablets is 10 mg orally once daily, administered with or without food.\n                     If as dose is missed, take the missed dose as soon as possible. Do not double the next dose.\n                     Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablets.\n                     Administer ezetimibe tablets at least 2 hours before or 4 hours after administration of a bile acid sequestrant [see Drug Interactions (7)].",
    "warningsAndPrecautions_original": "Ezetimibe Tablets\n                      USP, 10 mg white to off-white, capsule shaped beveled edge tablets debossed with \"K 31\" on one side and plain on other side. They are supplied as follows: \n                                  Bottles of 30                   NDC 59651-052-30             Bottles of 90                   NDC 59651-052-90             Bottles of 500                  NDC 59651-052-05\n                     \n                        \n                            Storage\n                        \n                     \n                      Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [see Adverse Reactions (6.2)].\n                  \n                  When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (5.1)]."
}